Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
28 hedge funds and large institutions have $225M invested in Sinovac Biotech, Ltd in 2026 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
0% more funds holding
Funds holding: 28 → 28 (0)
13% less capital inflows, than outflows
Capital inflows: $1.63K | Capital outflows: $1.86K
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.62K |
| 2 |
Morgan Stanley
New York
|
+$13 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$1.5K |
| 2 |
Horizon Investments
Charlotte,
North Carolina
|
-$336 |
| 3 |
Harbour Investments
Madison,
Wisconsin
|
-$32 |
SVA Hedge Fund Activity: Q2 2026 in Review
28 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q2 2026, worth a combined $225M — down 0% from $225M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SVA positions and 2 closed out — a net gain of 1 holder — while 3 added to existing stakes and 5 trimmed.
The largest buyer was UBS Group, adding an estimated $1.62K. The largest seller was Wells Fargo, cutting an estimated $1.5K.
- 28 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $225M of Sinovac Biotech, Ltd stock for Q2 2026, down 0% quarter-over-quarter.
- 3 funds opened new Sinovac Biotech, Ltd positions in Q2 2026 and 2 closed out, a net change of +1 holder.
- The largest Sinovac Biotech, Ltd buyer in Q2 2026 was UBS Group, an estimated $1.62K added.
- The largest Sinovac Biotech, Ltd seller in Q2 2026 was Wells Fargo, an estimated $1.5K sold.
Based on aggregated 13F filings for Q2 2026.